• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Maraviroc for HIV: Responses at 48 Weeks

  • — 20 Sep, 2007
AudioMedica News
AudioMedica News
Maraviroc for HIV: Responses at 48 Weeks
Maraviroc for HIV: Responses at 48 Weeks
00:00 /
RSS Feed
Share
Link
Embed
Jacob Lalezari
Jacob Lalezari

REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.

[audio:https://www.audiomedica.com/podcasting/general_medicine/070918JacobLalezari.mp3]

You may also like...

  • Ovarian Stimulation Does Not Affect Fetal Birth Weight – reporting from 23rd Annual Conference of the European Society of Human Reproduction and Embryology, 1-4  July 2007, Lyon, France Ovarian Stimulation Does Not Affect Fetal Birth Weight – reporting from 23rd Annual Conference of the European Society of Human Reproduction and Embryology, 1-4 July 2007, Lyon, France 2 Aug, 2007
  • Community-Associated MRSA: Public Housing, Jail: Risks? Community-Associated MRSA: Public Housing, Jail: Risks? 4 Jan, 2006
  • Lifestyle and Heart Disease in Europe: A Growing Problem Lifestyle and Heart Disease in Europe: A Growing Problem 2 Sep, 2007
  • Tuberculosis: Non-Adherence to Treatment is a Major Obstacle to Therapy Success Tuberculosis: Non-Adherence to Treatment is a Major Obstacle to Therapy Success 9 Aug, 2007
  • Previous story Starting Antiretroviral Therapy Can Trigger Leprosy
  • Next story Monoclonal Antibody to Help Treat HIV?
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Microbiome Diversity Key To Survival After Allogeneic…
    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with Chronic…
    • Which Tasks Most Influence Pediatric PT Productivity,…
  • Home
  • General Medicine
  • Maraviroc for HIV: Responses at 48 Weeks

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.